RESEARCH ARTICLE Effect of Urinary Protease Inhibitor (Ulinastatin) on Cardiopulmonary Bypass:

Objectives: A meta-analysis was conducted to investigate the effects of ulinastatin treatment on adult patients undergoing cardiac surgery under cardiopulmonary bypass (CPB). Methods: Seven electronic databases were searched for reports of randomized, controlled trials conducted up to February 2014 in which patients undergoing cardiac surgery with CPB were administered ulinastatin in the perioperative period. Results: Fifty-two studies with 2025 patients were retained for analysis. The results showed that the ulinastatin can attenuate the plasma levels of pro-inflammatory cytokines and enhance the anti-inflammatory cytokine levels in patients undergoing cardiac surgery with CPB. Meanwhile, the ulinastatin had a significant beneficial effect on myocardial injury. The mean differences (MD) and 95 % confidence intervals (95 % CI) of biochemical markers were 263.54 (279.36, 247.72) for lactate dehydrogenase, 2224.99 (2304.83, 2145.14) for creatine kinase, 28.75 (214.23, 23.28) for creatine kinase-MB, and 20.14 (20.20, 20.09] for troponin I (all P,0.01). However, neither hemodynamics nor cardiac function improved significantly, except that the MD and 95 % CI of mean arterial pressure were 2.50 (0.19, 4.80) (P50.03). There were no statistically significant differences in the use of inotropes, postoperative bleeding, postoperative complications, the intensive care unit (ICU) stay, and the hospital stay; however, the frequency of aut